WO2016175551A3 - 항체에 덴드론이 접합된 면역접합체 및 이의 용도 - Google Patents

항체에 덴드론이 접합된 면역접합체 및 이의 용도 Download PDF

Info

Publication number
WO2016175551A3
WO2016175551A3 PCT/KR2016/004398 KR2016004398W WO2016175551A3 WO 2016175551 A3 WO2016175551 A3 WO 2016175551A3 KR 2016004398 W KR2016004398 W KR 2016004398W WO 2016175551 A3 WO2016175551 A3 WO 2016175551A3
Authority
WO
WIPO (PCT)
Prior art keywords
dendron
antibody
immune conjugate
drugs
conjugated
Prior art date
Application number
PCT/KR2016/004398
Other languages
English (en)
French (fr)
Other versions
WO2016175551A2 (ko
Inventor
김영덕
박은지
김예진
신영기
최준영
Original Assignee
에이비온 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이비온 주식회사 filed Critical 에이비온 주식회사
Publication of WO2016175551A2 publication Critical patent/WO2016175551A2/ko
Publication of WO2016175551A3 publication Critical patent/WO2016175551A3/ko
Priority to US15/795,528 priority Critical patent/US10576158B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명에 따른 면역접합체는 표면에 다수의 약물을 결합시킬 수 있는 덴드론과 표적 지향적인 항체를 접합함으로써 표적 지향적인 약물치료에 이용될 수 있으며, 특히 다수의 항암제가 결합된 친수성 덴드론을 항체에 접합시킴으로써, 종양 특이적으로 높은 농도의 약물을 전달하여 강력한 항암효과를 나타낼 수 있는 약학적 조성물을 제공한다.
PCT/KR2016/004398 2015-04-27 2016-04-27 항체에 덴드론이 접합된 면역접합체 및 이의 용도 WO2016175551A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/795,528 US10576158B2 (en) 2015-04-27 2017-10-27 Immune conjugate having dendron conjugated to antibody and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150059264A KR102462811B1 (ko) 2015-04-27 2015-04-27 항체에 덴드론이 접합된 면역접합체 및 이의 용도
KR10-2015-0059264 2015-04-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/795,528 Continuation US10576158B2 (en) 2015-04-27 2017-10-27 Immune conjugate having dendron conjugated to antibody and use thereof

Publications (2)

Publication Number Publication Date
WO2016175551A2 WO2016175551A2 (ko) 2016-11-03
WO2016175551A3 true WO2016175551A3 (ko) 2016-12-22

Family

ID=57199298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/004398 WO2016175551A2 (ko) 2015-04-27 2016-04-27 항체에 덴드론이 접합된 면역접합체 및 이의 용도

Country Status (3)

Country Link
US (1) US10576158B2 (ko)
KR (1) KR102462811B1 (ko)
WO (1) WO2016175551A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
CN107937443B (zh) * 2017-11-10 2021-12-21 上海交通大学 一种适用于核酸转染的自组装纳米制剂及其制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305481B1 (en) 1987-03-20 1993-09-29 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
WO1988007085A1 (en) 1987-03-20 1988-09-22 Creative Biomolecules, Inc. Process for the purification of recombinant polypeptides
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
US7977452B2 (en) * 2005-03-28 2011-07-12 Dendritic Nanotechnologies, Inc. Janus dendrimers and dendrons
US10029014B2 (en) * 2013-09-10 2018-07-24 The Research Foundation For The State University Of New York Synthesis of novel asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeting drug delivery

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NWE, K. ET AL.: "Preparation of Cystamine Core Dendrimer and Antibody-dendrimer Conjugates for MRI Angiography.", MOLECULAR PHARMACEUTICS, vol. 9, no. 3, 2012, pages 374 - 381, XP055339190 *
SHE, W. ET AL.: "The Potential of Self-assembled, pH-responsive Nanoparticles of mPEGylated Peptide Dendron-doxorubicin Conjugates for Cancer Therapy.", BIOMATERIALS, vol. 34, 2013, pages 1613 - 1623, XP028960621 *
THOMAS, T. P. ET AL.: "In Vitro Targeting of Synthesized Antibody-conjugated Dendrimer Nanoparticles.", BIOMACROMOLECULES, vol. 5, 2004, pages 2269 - 2274, XP001222012 *
ZHU, S. ET AL.: "Partly PEGylated Polyamidoamine Dendrimer for Tumor-selective Targeting of Doxorubicin: The Effects of PEGylation Degree and Drug Conjugation Style.", BIOMATERIALS, vol. 31, 2010, pages 1360 - 1371, XP026814166 *
ZHU, S. ET AL.: "RGD-modified PEG-PAMAM-DOX Conjugate: In Vitro and in Vivo Targeting to Both Tumor Neovascular Endothelial Cells and Tumor Cells.", ADVANCED MATERIALS, vol. 23, no. 12, 2011, pages H84 - H89, XP055339223 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート

Also Published As

Publication number Publication date
KR20160127601A (ko) 2016-11-04
KR102462811B1 (ko) 2022-11-04
US10576158B2 (en) 2020-03-03
US20180110860A1 (en) 2018-04-26
WO2016175551A2 (ko) 2016-11-03

Similar Documents

Publication Publication Date Title
WO2016161342A3 (en) Nitrobenzyl derivatives of anti-cancer agents
WO2015095227A3 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
SG11201807936VA (en) Cell injury inducing therapeutic drug for use in cancer therapy
EP4233909A3 (en) Anti-cmet antibody drug conjugates and methods for their use
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
WO2016004048A3 (en) Targeted conjugates and particles and formulations thereof
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
WO2020056198A3 (en) Substituted benzazepine compounds, conjugates, and uses thereof
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
WO2014135282A8 (en) Amatoxin derivatives
WO2015095301A3 (en) Cytotoxic peptides and conjugates thereof
WO2017062619A3 (en) Combination therapy for the treatment of cancer
NZ754810A (en) Pyrrolobenzodiazepine-antibody conjugates
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
MX2020004691A (es) Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
WO2015123576A3 (en) Targeted nanoparticle compositions and methods of their use to treat obesity
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
MY196747A (en) Cell injury inducing therapeutic drug for use in cancer therapy
WO2016147031A3 (en) Novel hydrophilic linkers and ligand-drug conjugates thereof
WO2015114166A3 (en) Targeted drug conjugates
MX2018014576A (es) Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos.
WO2016175551A3 (ko) 항체에 덴드론이 접합된 면역접합체 및 이의 용도
WO2017062615A3 (en) Combination therapy for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16786737

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27/03/2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16786737

Country of ref document: EP

Kind code of ref document: A2